Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ESO-T01
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : AstraZeneca
Deal Size : $1,000.0 million
Deal Type : Acquisition
AstraZeneca Boosts Cancer Therapies with $1B EsoBiotec Buy
Details : Through the acquisition, AstraZeneca will leverage EsoBiotec ENaBL platform and their products including ESO-T01. It is being evaluated for r/r Multiple Myeloma.
Product Name : ESO-T01
Product Type : Cell and Gene therapy
Upfront Cash : $1,000.0 million
March 17, 2025
Lead Product(s) : ESO-T01
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : AstraZeneca
Deal Size : $1,000.0 million
Deal Type : Acquisition
EsoBiotec Doses First Patient in BCMA CAR-T ESO-T01 Trial for Multiple Myeloma
Details : ESO-T01 is an immune shielded lentiviral vector that reprograms T lymphocytes in vivo into highly effective BCMA CAR-T cells, for the treatment of r/r multiple myeloma.
Product Name : ESO-T01
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 08, 2025
EsoBiotec Begins Clinical Trial of BCMA CAR-T Candidate ESO-T01 for Multiple Myeloma
Details : ESO-T01 is an immune shielded lentiviral vector that reprograms T lymphocytes in vivo into highly effective BCMA CAR-T cells, for the treatment of multiple myeloma.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Not Applicable
December 11, 2024
Reset All
